1. Home
  2. FRAF vs IFRX Comparison

FRAF vs IFRX Comparison

Compare FRAF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

HOLD

Current Price

$62.76

Market Cap

281.2M

Sector

Finance

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.70

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRAF
IFRX
Founded
1906
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.2M
303.4M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
FRAF
IFRX
Price
$62.76
$1.70
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
32.0K
972.4K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
2.46%
N/A
EPS Growth
88.84
N/A
EPS
1.48
N/A
Revenue
N/A
N/A
Revenue This Year
$14.44
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
$42.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.52
$0.74
52 Week High
$64.88
$2.95

Technical Indicators

Market Signals
Indicator
FRAF
IFRX
Relative Strength Index (RSI) 50.84 36.69
Support Level $54.80 $1.54
Resistance Level $64.00 $1.71
Average True Range (ATR) 2.11 0.12
MACD -0.09 -0.02
Stochastic Oscillator 54.94 10.75

Price Performance

Historical Comparison
FRAF
IFRX

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: